NEW YORK, Jan. 26, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against HeartWare International, Inc. (“Heartware” or the “Company”) (Nasdaq:HTWR) in the United States District Court for the Southern District of New York on behalf of a class consisting of all persons or entities who purchased HeartWare securities between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the Company and certain of its senior executives violated provisions of the Exchange Act by making numerous false and misleading statements and omissions of material fact, including in press releases and in statements during conferences and conference calls with analysts and investors. Specifically, the Complaint alleges that after the U.S. Food and Drug Administration (“FDA”) issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that they therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Instagram Outage Disrupts Thousands of U.S. Users 



